Linagliptin: A comprehensive profile
Funding Sponsor
American University in Cairo
Author's Department
Chemistry Department
Second Author's Department
Chemistry Department
Third Author's Department
Chemistry Department
Find in your Library
https://doi.org/10.1016/bs.podrm.2024.10.001
Document Type
Research Article
Publication Title
Profiles of Drug Substances Excipients and Related Methodology
Publication Date
1-1-2025
doi
10.1016/bs.podrm.2024.10.001
Abstract
Linagliptin (LINA) is the first dipeptidyl peptidase IV (DPP-IV) inhibitor that could be administered orally to control hyperglycemia. It is indicated for controlling adult blood sugar levels that are diagnosed with diabetes mellitus type II. The current chapter provides a complete review of LINA including nomenclature, physiochemical characteristics, synthesis, and thermal analysis. Additionally, different analytical techniques used for quantitative and qualitative determination of LINA are presented.
First Page
97
Last Page
123
Recommended Citation
APA Citation
Kabil, M.
Lababidi, J.
&
Azzazy, H.
(2025). Linagliptin: A comprehensive profile. Profiles of Drug Substances Excipients and Related Methodology, 50, 97–123.
https://doi.org/10.1016/bs.podrm.2024.10.001
MLA Citation
Kabil, Mohamed Fawzy, et al.
"Linagliptin: A comprehensive profile." Profiles of Drug Substances Excipients and Related Methodology, vol. 50, 2025, pp. 97–123.
https://doi.org/10.1016/bs.podrm.2024.10.001